13. Multiple sclerosis/Neuromyelitis optica
3,050 clinical trials,   2,147 drugs   (DrugBank: 348 drugs),   244 drug target genes,   228 drug target pathways

Searched query = "Multiple sclerosis/Neuromyelitis optica", "Multiple sclerosis", "Neuromyelitis optica", "MS", "NMOSD", "Devic disease", "Balo concentric sclerosis", "Baló concentric sclerosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02493049
(ClinicalTrials.gov)
August 20152/7/2015Pilot Trial of Domperidone in Relapsing-Remitting Multiple Sclerosis (RRMS)Randomized, Controlled Pilot Trial of Domperidone in Relapsing-Remitting Multiple SclerosisMultiple Sclerosis, Relapsing-RemittingDrug: DomperidoneUniversity of CalgaryAlberta Innovates Health SolutionsCompleted18 Years60 YearsAll17Phase 2Canada
2NCT02308137
(ClinicalTrials.gov)
February 20152/12/2014Domperidone in Secondary Progressive Multiple Sclerosis (SPMS)Open-label, Single-center, Single-arm Futility Trial Evaluating Oral Domperidone 10mg QID for Reducing Progression of Disability in Patients With Secondary Progressive Multiple Sclerosis (SPMS)Multiple Sclerosis, Secondary ProgressiveDrug: DomperidoneUniversity of CalgaryAlberta Innovates Health SolutionsCompleted18 Years60 YearsAll64Phase 2Canada